Compare SQNS & ATYR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SQNS | ATYR |
|---|---|---|
| Founded | 2003 | 2005 |
| Country | France | United States |
| Employees | N/A | N/A |
| Industry | Semiconductors | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 85.3M | 69.2M |
| IPO Year | 2011 | 2015 |
| Metric | SQNS | ATYR |
|---|---|---|
| Price | $5.32 | $0.72 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 3 | 5 |
| Target Price | ★ $21.33 | $8.75 |
| AVG Volume (30 Days) | 206.8K | ★ 1.5M |
| Earning Date | 02-10-2026 | 03-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $31,534,000.00 | $190,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $70.61 | $18,728.88 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 3.20 | N/A |
| 52 Week Low | $4.44 | $0.64 |
| 52 Week High | $58.30 | $7.29 |
| Indicator | SQNS | ATYR |
|---|---|---|
| Relative Strength Index (RSI) | 49.60 | 46.66 |
| Support Level | $5.13 | $0.69 |
| Resistance Level | $5.50 | $0.76 |
| Average True Range (ATR) | 0.27 | 0.04 |
| MACD | 0.07 | 0.00 |
| Stochastic Oscillator | 48.55 | 53.27 |
Sequans Communications SA is a designer, developer, and supplier of cellular semiconductor solutions for broadband Internet of Things (IoT) markets. Its offer 5G/4G chips and modules fully optimized for non-smartphone devices. The company covers applications such as smart mobility and logistics, smart utility meters, smart cities, smart industries, e-health and wellness, and smart homes to name few. The Company has one operating segment, which is the design and marketing of semiconductor components for cellular wireless systems. Its geographical segments are Taiwan, Korea, China (including Hong Kong), the Rest of Asia, the United States and the Rest of the world.
aTyr Pharma Inc is a biotherapeutics company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform. The company has concentrated its research and development efforts on a newly discovered area of biology, the extracellular functionality and signaling pathways of tRNA synthetases. Its primary focus is efzofitimod, a clinical-stage product candidate which targets NRP2 to resolve chronic inflammation that can cause to fibrosis. Efzofitimod has a novel mechanism of action for potentially treating lung inflammation and fibrosis.